Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome

Overview

AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).

AIHA occurs in \~10-12% of APS cohorts and is associated with arterial thrombosis, cardiac valve disease, livedo reticularis, epilepsy/chorea, and a more severe APS phenotype. APS patients hospitalized with AIHA have markedly higher venous thromboembolism (VTE) risk (OR ≈ 8.6) compared with AIHA without APS. Hematologic APS (AIHA ± thrombocytopenia) may precede or coexist with thrombotic/obstetric APS, depending on aPL profile. There is a need to systematically define the clinical implications (thrombosis, organ involvement, outcomes) of AIHA in APS.

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts